ClinicalTrials.gg

TargetBeta

CCR8

C-C motif chemokine receptor 8 · also CY6, TER1, CKR-L1, GPR-CY6 · CD molecules

7 programs in company-led studies act on CCR8, from 7 companies: 1 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
cafelkibartSino Biopharmaceuticalphase 375 running–the company's pipeline
denikitugruleGilead Sciencesphase 233 running–NCIt
imzokitugBristol-Myers Squibbphase 222 running–a judged reading
CCR8 Inhibitor IPG7236ruleNanjing Immunophage Biotechphase 231 running–NCIt
Anti-CCR8 Antibody-drug Conjugate TAK-188ruleTakedaphase 211 running–NCIt
Anti-CCR8 Monoclonal Antibody HC006ruleHC Biopharmaphase 122 running–NCIt
azirkitugAbbViephase 111 running–the company's pipeline

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.